Hikma Pharmaceuticals PLC Stock

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Real-time Estimate Cboe Europe 05:36:39 2024-05-23 am EDT 5-day change 1st Jan Change
1,969 GBX +1.55% Intraday chart for Hikma Pharmaceuticals PLC -0.61% +10.17%
Sales 2024 * 2.99B Sales 2025 * 3.09B Capitalization 5.48B
Net income 2024 * 414M Net income 2025 * 451M EV / Sales 2024 * 2.12 x
Net Debt 2024 * 852M Net Debt 2025 * 607M EV / Sales 2025 * 1.97 x
P/E ratio 2024 *
13.5 x
P/E ratio 2025 *
12.4 x
Employees 9,100
Yield 2024 *
2.88%
Yield 2025 *
3.06%
Free-Float 65.59%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hikma Pharmaceuticals PLC

1 day+1.55%
1 week-0.61%
Current month+2.44%
1 month+8.36%
3 months-4.97%
6 months+12.44%
Current year+10.17%
More quotes
1 week
1 904.00
Extreme 1904
1 991.00
1 month
1 750.00
Extreme 1750
2 036.00
Current year
1 750.00
Extreme 1750
2 165.00
1 year
1 711.00
Extreme 1711
2 222.00
3 years
1 174.50
Extreme 1174.5
2 703.00
5 years
1 174.50
Extreme 1174.5
2 768.00
10 years
814.20
Extreme 814.2
2 768.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 89-12-31
Director of Finance/CFO 52 00-12-31
Chairman 67 80-12-31
Members of the board TitleAgeSince
Director/Board Member 66 20-04-30
Director/Board Member 72 16-09-30
Director/Board Member 62 22-10-31
More insiders
Date Price Change Volume
24-05-23 1,971 +1.65% 14 571
24-05-22 1,939 +0.36% 602,872
24-05-21 1,932 -2.08% 281,094
24-05-20 1,973 -0.25% 116,701
24-05-17 1,978 -0.25% 219,724

Delayed Quote London S.E., May 23, 2024 at 05:20 am EDT

More quotes
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
24.68 USD
Average target price
28.68 USD
Spread / Average Target
+16.21%
Consensus

Quarterly revenue - Rate of surprise